STEMLINE THERAPEUTICS INC Form 8-K June 23, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 23, 2015

Stemline Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Number) 45-0522567 (IRS Employer Identification No.)

750 Lexington Avenue

Eleventh Floor

New York, New York 10022

Edgar Filing: STEMLINE THERAPEUTICS INC - Form 8-K

(Address of Principal Executive Offices)

(646) 502-2311

(Registrant s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

0	Written communications pursuant to Rule 425 under the Securities Act.
0	Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
0	Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
0	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Edgar Filing: STEMLINE THERAPEUTICS INC - Form 8-K

Item 5.07. Submission of Matters to a Vote of Security Holders.

The 2015 annual meeting of stockholders of Stemline Therapeutics, Inc. (Stemline) was held on June 23, 2015. The following matters were voted on by the stockholders: the election of three directors, the ratification of the appointment of Ernst & Young LLP as Stemline s independent registered public accounting firm for the year ending December 31, 2015, and the approval of the Stemline Employee Share Purchase Plan.

The vote with respect to the nominees for director is set forth below:

		Total Votes		
Nominee	Total Votes For	Withheld	Broker Non-Votes	
Ivan Bergstein, M.D.	11,993,458	72,688	2,831,401	
J. Kevin Buchi	8,036,115	4,030,031	2,831,401	
Alan Forman	12,032,759	33,387	2,831,401	

The vote with respect to the ratification of the appointment of Ernst & Young LLP as Stemline s independent registered public accounting firm for the year ending December 31, 2015 is set forth below:

Total Votes For	Total Votes Against	Abstention	Broker Non-Votes
14,882,57	10,028	4,945	0

The vote with respect to the approval of the Stemline Employee Share Purchase Plan is set forth below:

Total Votes For	Total Votes Against	Abstention	Broker Non-Votes
11,995,818	39,278	31,050	2,831,401

2

Edgar Filing: STEMLINE THERAPEUTICS INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Stemline Therapeutics, Inc. (Registrant)

Date: June 23, 2015

By:

/s/ Kenneth Hoberman Kenneth Hoberman Chief Operating Officer

3